New study sheds light on best treatment for older breast cancer patients
NCT ID NCT06086340
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical records of 779 older adults (65+) with a certain type of advanced breast cancer (HR+/HER2-). It compared survival in those who received a combination of the drug palbociclib plus hormone therapy versus hormone therapy alone. The goal was to see which approach helped patients live longer. The study did not involve new treatments but analyzed existing data to understand real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States